SEI Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

SEI Investments’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-38,935	Closed	-$273K	–	2535
2020 Q4	$273K	Sell	38,935 -98,223	-72%	-$764K	﹤0.01%	2247
2020 Q3	$1.12M	Sell	137,158 -754	-0.5%	-$4.67K	﹤0.01%	1554
2020 Q2	$949K	Buy	137,912 +31,080	+29%	+$168K	﹤0.01%	1580
2020 Q1	$507K	Buy	106,832 +68,421	+178%	+$394K	﹤0.01%	1735
2019 Q4	$335K	Buy	+38,411	New	+$208K	﹤0.01%	2109
2018 Q1	–	Sell	-31	Closed	–	–	3732
2017 Q4	$0	Hold	31	–	–	﹤0.01%	3550
2017 Q3	$0	Buy	+31	New	+$438	﹤0.01%	3452

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SEI Investments's JNCE Position: Q1 2021 in Review

SEI Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2021, closing a stake of 38,935 shares — an estimated $273K sold.

SEI Investments first reported a position in JNCE in Q3 2017 and held it in 7 quarters. The position peaked at $1.12M in Q3 2020. 124 funds tracked by Wall St. Rank hold JNCE as of Q1 2021.

SEI Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
SEI Investments sold 38,935 Jounce Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $273K.
SEI Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 7 quarters.
SEI Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $1.12M in Q3 2020.
124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2021.

Based on SEI Investments's 13F filing for Q1 2021, filed 12 May 2021.